Drug Insight: Gastrointestinal stromal tumors (GIST) - The solid tumor model for cancer-specific treatment

Nature Clinical Practice Oncology

Volumn 5, Issue 2, 2008, Pages 102-111

  Sleijfer, Stefan ^a   Wiemer, Erik ^a   Verweij, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AB 1010; ANTINEOPLASTIC AGENT; CEDIRANIB; EVEROLIMUS; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; MASATINIB; MIDOSTAURIN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NILOTINIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; VATALANIB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CARDIOMYOPATHY; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; HUMAN; INCIDENCE; NAUSEA; NEUTROPENIA; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; REVIEW; SYMPTOMATOLOGY; TUMOR MODEL; VOMITING;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION;

EID: 38849194018     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1037     Document Type: Review

References (68)

1. Corless CL et al. (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3813-3825
2. Tornillo L et al. (2005) An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 59: 557-563
3. Hirota S et al. (1998) Gain-of-function mutations of c-KIT in human gastro-intestinal tumors. Science 279: 577-580
4. Heinrich MC et al. (2003) Kinase mutations and imatinib responses in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 21: 4342-4349
5. Debiec-Rychter M et al. (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689-695
6. Debiec-Rychter M et al. (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of PKC412 against imatinib-resistant mutants. Gastroenterology 128 270-279
7. Antonescu CR et al. (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10: 3282-3290
8. Heinrich MC et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710
9. Rubin BP et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumor. Cancer Res 61: 8118-8121
10. Fletcher CDM et al. (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459-465
11. Nilsson B et al. (2005) Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate area. Cancer 103: 821-829
12. DeMatteo RP et al. (2000) Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-58
13. Imamura M et al. (2007) Prognostic significance of angiogenesis in gastrointestinal stromal tumors. Mod Pathol 20: 529-537
14. Miettinen M et al. (2005) Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29: 52-68
15. Miettinen M et al. (2006) Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30: 477-489
16. El-Rifai W et al. (2000) DNA sequence copy number changes in gastrointestinal stromal tumors: Tumor progression and prognostic significance. Cancer Res 60: 3899-3903
17. Schneider-Stock R et al. (2005) Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: A tissue microarray study. Clin Cancer Res 11: 638-645
18. INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: Prognostic implications and correlations with risk stratification of NIH consensus. Ann Surg Oncol 13: 1633-1644
19. House MG et al. (2003) Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 7: 1004-1014
20. Sleijfer S et al. (2006) Gastrointestinal stromal tumors. In: UICC: Prognostic Factors in Cancer, edn 3, 187-191 (Eds Gospodarowicz MK et al.) New Jersey: John Wiley & Sons
21. Singer S et al. (2002) Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20: 3898-3905
22. Wardelmann E et al. (2003) Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 106: 887-895
23. DeMatteo R et al. (2007) Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 [abstract 10079]. Proc Am Soc Clin Oncol 25
24. Van Glabbeke M et al. (2002) Progression-free rate as the principal end point for phase II trials in soft tissue sarcomas. Eur J Cancer 38: 543-549
25. Verweij J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: A randomised trial. Lancet 364: 1127-1134
26. Fabian MA et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336
27. Van Oosterom AT et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358: 1421-1423
28. Demetri GD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 472-480
29. Verweij J et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumors, but does not yield responses in other soft tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma phase II study. Eur J Cancer 39: 2006-2011
30. Van Glabbeke M et al. (2007) Comparison of two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): A meta-analysis based on 1640 patients [abstract 10004]. Proc Am Soc Clin Oncol 25
31. Blanke CD et al. (2006) Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor patients treated with imatinib mesylate [abstract 9528]. Proc Am Soc Clin Oncol 24
32. Blay J-Y et al. (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 25: 1107-1113
33. Kerkela R et al. (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12: 908-916
34. Verweij J et al. (2007) Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 43: 974-978
35. Van Glabbeke M et al. (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42: 2277-2285
36. Van Glabbeke et al. (2007) Interactive risk calculator for predicting toxicities in patients with advanced gastro-intestinal stromal tumors (GIST) treated with imatinib mesylate. www.eortc.be/tools/ imatinibtoxicity (accessed 10 May 2007)
37. Bechtold RE et al (2003) Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging 28: 808-814
38. Linton KM et al. (2006) Response evaluation in gastrointestinal stromal tumours treated with imatinib: Misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 79: E40-e44
39. Loughrey MB et al. (2005) Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 58: 779-781
40. Choi H et al. (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759
41. Benjamin RS et al. (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760-1764
42. Van Glabbeke M et al. (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation of Treatment and Research of Cancer - Italian Sarcoma Group - Australasian Gastrointestinal Trials Group Study. J Clin Oncol 23: 5795-5804
43. Heinrich MC et al. (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 4764-4774
44. Debiec-Rychter M et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093-1103
45. Wardelmann E et al. (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743-1749
46. Antonescu CR et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190
47. Tamborini E et al. (2006) Functional analyses and molecular modelling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 25: 6140-6146
48. Fletcher JA et al. (2003) Mechanisms of resistance to imatinib (IM) in advanced gastrointestinal stromal tumors (GIST) [abstract 3275]. Proc Am Soc Clin Oncol 22
49. Theou N et al. (2005) Multidrug resistance proteins in gastrointestinal stromal tumors: Site-dependent expression and initial response to imatinib. Clin Cancer Res 11: 7593-7598
50. Mahon FX et al. (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 2368-2373
51. Burger H et al. (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942
52. Gambacorti-Passerini C et al. (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9: 625-632
53. Delbado C et al. (2006) Pharmacokinetic-pharmadynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12 6073-6078
54. Judson IR et al. (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time. Cancer Chemother Pharmacol 55 379-386
55. Zalcberg JR et al. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41: 1751-1757
56. Prenen H et al. (2006) Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 2622-2627
57. Bui BN et al. (2007) Preliminary efficacy and safety results of masitinib administered, front line in patients with advanced GIST. A phase II study [abstract 10025]. Proc Am Soc Clin Oncol 25
58. Joensuu H et al. (2006) A phase II, open-label study of PTK787/ ZK222584 in the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate [abstract 9531]. Proc Am Soc Clin Oncol 24
59. Reichardt P et al. (2005) A phase I/II trial of the oral PKC-inhibitor PKC412 in combination with imatinib mesylate (IM) in patients with gastrointestinal stromal tumors refractory to IM [abstract 3016]. Proc Am Soc Clin Oncol 23
60. Von Mehren M et al. (2007) A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - study update [abstract 10023]. Proc Am Soc Clin Oncol 25
61. Demetri GD et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumours after failure of imatinib: A randomised controlled trial. Lancet 368: 1329-1338
62. Heinrich M et al. (2006) Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFRA mutations [abstract 9502]. Proc Am Soc Clin Oncol 24
63. Van Oosterom A et al. (2005) A phase I/II trial of the oral mTOR-inhibitor everolimus and imatinib mesylate (IM) in patients with gastrointestinal stromal tumor refractory to IM [abstract 9033]. Proc Am Soc Clin Oncol 23
64. Steinert DM et al. (2006) Expression of Bcl-2 in gastrointestinal stromal tumors. Cancer 106: 1617-1623
65. Takahashi R et al. (2003) Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64: 266-274
66. Salto-Tellez M et al. (2007) Tissue microarrays characterize the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br J Cancer 96: 776-782
67. Bauer S et al. (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66: 9153-9161
68. Demetri GD et al. (2007) Inhibition of the heat shock protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial [abstract 10024]. Proc Am Soc Clin Oncol 25